Biomerica Reports Third Quarter Fiscal 2026 Financial Results

Why It Matters

The Medicare reimbursement and European regulatory wins unlock broader payer coverage and market access, positioning Biomerica’s diagnostic portfolio for higher‑margin growth. Improved loss metrics signal the company’s restructuring toward profitable, diagnostics‑driven revenue streams.

Key Takeaways

• inFoods IBS achieved 59.4% pain reduction in real‑world study
• CMS set $300 Medicare reimbursement for inFoods IBS test
• European revenue rose 45% to $287,000, driven by hp+detect
• R&D spending fell 24% as hp+detect moves to commercialization
• Net loss per share improved 37% to $0.92 in nine months

Pulse Analysis

Biomerica’s inFoods® IBS test is gaining traction as a precision‑dietary therapy for the $10 billion U.S. irritable bowel syndrome market. The latest real‑world data, showing nearly 60% of patients experience meaningful pain relief and over two‑thirds see bloating reduction, validates the test’s clinical utility and differentiates it from generic symptom‑management approaches. By linking a finger‑stick blood assay to personalized nutrition plans, the company taps into growing consumer demand for non‑pharmaceutical, data‑driven health solutions, which could accelerate adoption in primary‑care settings.

The $300 Medicare payment rate announced by CMS removes a major reimbursement barrier, effectively guaranteeing coverage for millions of seniors who suffer from IBS. Coupled with the recent UK Medicines and Healthcare products Regulatory Agency registration of hp+detect™ and a 45% surge in European revenue, Biomerica is building a multi‑regional footprint. The first commercial order from a large European lab chain not only provides immediate sales but also serves as a reference client that can open doors to broader EU laboratory networks, expanding the addressable market for its H. pylori diagnostic platform.

Financially, the company’s shift from a development‑heavy cost structure to a commercialization focus is evident. R&D outlays dropped 24% year‑to‑date, while operating expenses remained flat, helping narrow the nine‑month net loss per share to $0.92, a 37% improvement. CEO Zack Irani’s emphasis on scaling CDMO services and higher‑margin diagnostics suggests a strategic pivot toward sustainable profitability. If payer acceptance and European regulatory momentum continue, Biomerica could see margin expansion and a more diversified revenue mix in the coming fiscal year.